Drug Resistance, Multiple

• 

  Subject Areas on Research

  • A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. 
  • A prospective observational study of the effect of penicillin skin testing on antibiotic use in the intensive care unit. 
  • A structure-based mechanism for drug binding by multidrug transporters. 
  • ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. 
  • Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells. 
  • Can prenylcysteines be exploited as ligands for mammalian multidrug-resistance transporters? 
  • Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells. 
  • Clinical Outcomes and Healthcare Utilization Related to Multidrug-Resistant Gram-Negative Infections in Community Hospitals. 
  • Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. 
  • Crystal structure of MtaN, a global multidrug transporter gene activator. 
  • Crystal structures of QacR-diamidine complexes reveal additional multidrug-binding modes and a novel mechanism of drug charge neutralization. 
  • Direct allelic variation scanning of the yeast genome. 
  • Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. 
  • Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. 
  • Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. 
  • Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. 
  • Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae. 
  • High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. 
  • Imaging drug resistance with radiolabeled molecules. 
  • Immunomodulator effect of picroliv and its potential in treatment against resistant Plasmodium yoelii (MDR) infection in mice. 
  • Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 
  • Infections caused by multidrug resistant organisms are not associated with overall, all-cause mortality in the surgical intensive care unit: the 20,000 foot view. 
  • Infections in patients with cystic fibrosis following lung transplantation. 
  • Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. 
  • Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. 
  • Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. 
  • Multidrug resistance in ocular melanoma. 
  • National Department of Defense Surveillance for Invasive Streptococcus pneumoniae: antibiotic resistance, serotype distribution, and arbitrarily primed polymerase chain reaction analyses. 
  • P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). 
  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. 
  • Point-of-prescription interventions to improve antimicrobial stewardship. 
  • Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. 
  • Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. 
  • Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. 
  • Status of the Prevention of Multidrug-Resistant Organisms in International Settings: A Survey of the Society for Healthcare Epidemiology of America Research Network. 
  • The future of therapy for childhood rhabdomyosarcoma: clues from molecular biology. 
  • The staphylococcal QacR multidrug regulator binds a correctly spaced operator as a pair of dimers. 
  • The structural mechanism for transcription activation by MerR family member multidrug transporter activation, N terminus. 
  • Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells. 
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. 
  • When should contact precautions and active surveillance be used to manage patients with multidrug-resistant enterobacteriaceae? 
  • [Epidemiology of chemoresistant Plasmodium falciparum]. 
  • kdr-Type resistance in insects with special reference to the German cockroach, Blattella germanica. 
• 

  Keywords of People

  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology